Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Drug Profile

Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Alternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Anti-Sialyl-Tn antibodies; Anti-Sialyl-Tn monoclonal antibodies; Anti-STn antibodies; Humanised anti-Sialyl-Tn anti-CD3 bispecific antibodies; ST1 antibody drug conjugate programme

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Sialix
  • Developer Massachusetts General Hospital; Siamab Therapeutics
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates
  • Mechanism of Action Polysaccharide inhibitors; Sialosyl Tn antigen inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Research Cancer

Most Recent Events

  • 08 Jun 2017 Siamab Therapeutics plans a phase I trial of ST1 antibody drug conjugate programme for Cancer in 2019
  • 04 Apr 2017 Pharmacodynamics data from two preclinical studies in Ovarian and Colorectal cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top